Peroxiredoxin 3 Inhibits Cardiac Fibrosis in Mice via NOX4-P38 Signalling. DOI

Xiaoqi Xiong,

Jun Li, Zhen Chen

и другие.

PubMed, Год журнала: 2023, Номер 25(6), С. 391 - 398

Опубликована: Июнь 28, 2023

Peroxiredoxin-3 (Prx-3) is widely acknowledged as an antioxidant that protects against mitochondrial reactive oxygen species. Nonetheless, its role in cardiac fibrosis has not been elucidated. We aim to explore the and mechanism of Prx-3 fibrosis.In this experimental study, mice received subcutaneous injections isoproterenol (ISO) for 14 consecutive days (10 mg/kg/d three days, followed by 5 11 days) establish a model. The were subsequently injected with adenovirus-Prx-3 (ad-Prx-3) enable overexpression. Echocardiography was used evaluate function. Mice heart fibroblasts isolated stimulated transforming growth factor β1 (TGFβ1) induce vitro. Cells also transfected ad-Prx-3 overexpression Prx-3.Echocardiographic diameters markers indicated could inhibit ISO-induced dysfunction fibrosis. Fibroblasts exhibited reduced activation, proliferation, collagen transcription. found expression NADPH oxidase 4 (NOX4) P38 levels. After treatment inhibitor, overexpression-induced anti-fibrosis effect mitigated.Prx-3 protect inhibiting NOX4-P38 pathway.

Язык: Английский

The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases DOI Creative Commons
Antero Salminen

Journal of Molecular Medicine, Год журнала: 2024, Номер 102(6), С. 733 - 750

Опубликована: Апрель 11, 2024

Abstract The accumulation of senescent cells within tissues is a hallmark the aging process. Senescent are also commonly present in many age-related diseases and cancer microenvironment. escape abnormal from immune surveillance indicates that there some defect function cytotoxic cells, e.g., CD8 + T natural killer (NK) cells. Recent studies have revealed expression programmed death-ligand 1 (PD-L1) protein abundantly increased An increase amount PD-L1 protects clearance by PD-1 checkpoint receptor In fact, activation suppresses properties NK promoting state immunosenescence. inhibitory PD-1/PD-L1 pathway acts cooperation with immunosuppressive cells; for example, can enhance differentiation regulatory (Treg), myeloid-derived suppressor (MDSC), M2 macrophages, whereas cytokines secreted stimulate protein. Interestingly, signaling pathways known to promote cellular senescence process crucial stimulators protein, epigenetic regulation, inflammatory mediators, mTOR-related signaling, cGAS-STING pathway, AhR signaling. It seems axis has role thus it promotes tissues. Thus, blockade might be potential anti-aging senolytic therapy. Key messages accumulate during diseases. able Expression markedly increases Age-related stimulates Inhibitory

Язык: Английский

Процитировано

21

Cellular senescence of renal tubular epithelial cells in acute kidney injury DOI Creative Commons
Juan Chen,

Huhai Zhang,

Xiangling Yi

и другие.

Cell Death Discovery, Год журнала: 2024, Номер 10(1)

Опубликована: Фев. 5, 2024

Abstract Cellular senescence represents an irreversible state of cell-cycle arrest during which cells secrete senescence-associated secretory phenotypes, including inflammatory factors and chemokines. Additionally, these exhibit apoptotic resistance phenotype. serves a pivotal role not only in embryonic development, tissue regeneration, tumor suppression but also the pathogenesis age-related degenerative diseases, malignancies, metabolic kidney diseases. The renal tubular epithelial (RTEC) constitutes critical cellular event progression acute injury (AKI). RTEC inhibits regeneration repair processes and, concurrently, promotes transition AKI to chronic disease via mechanisms underlying are multifaceted include telomere shortening or damage, DNA mitochondrial autophagy deficiency, disorders, endoplasmic reticulum stress, epigenetic regulation. Strategies aimed at inhibiting senescence, targeting clearance senescent RTEC, promoting apoptosis hold promise for enhancing prognosis AKI. This review primarily focuses on characteristics impact intervening AKI, aiming provide foundation understanding providing potentially effective approaches treatment.

Язык: Английский

Процитировано

20

Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with other cardiovascular diseases DOI
Keiichi Torimoto,

Katherine J. Elliott,

Yuki Nakayama

и другие.

Cardiovascular Research, Год журнала: 2024, Номер 120(6), С. 567 - 580

Опубликована: Фев. 23, 2024

Abstract Hypertension is a major cause of cardiovascular diseases such as myocardial infarction and stroke. Cardiovascular fibrosis occurs with hypertension contributes to vascular resistance, aortic stiffness, cardiac hypertrophy. However, the molecular mechanisms leading fibroblast activation in remain largely unknown. There are two types fibrosis: replacement reactive fibrosis. Replacement response loss viable tissue form scar. Reactive an increase mechanical neurohormonal stress. Although both considered adaptive processes, they become maladaptive when too large, or stress persists. Myofibroblasts represent subpopulation activated fibroblasts that have gained contractile function promote wound healing. Therefore, myofibroblasts critical cell type promotes were recognized participating fibrosis, recent experimental evidence indicated there distinct populations Accordingly, we will discuss updated definition subpopulations, regulatory mechanisms, their potential roles pathophysiology utilizing new knowledge from various lineage tracing single-cell RNA sequencing studies. Among highlight novel matrifibrocytes immune fibrocytes including models hypertension, pressure overload, infarction, atherosclerosis, aneurysm, nephrosclerosis. Exploration into involved differentiation those subpopulations may lead treatments for end-organ damage associated other diseases.

Язык: Английский

Процитировано

10

Senescence and tissue fibrosis: opportunities for therapeutic targeting DOI
Steven O’Reilly, Pei‐Suen Tsou, John Varga

и другие.

Trends in Molecular Medicine, Год журнала: 2024, Номер unknown

Опубликована: Июнь 1, 2024

Язык: Английский

Процитировано

8

Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer DOI Creative Commons

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

и другие.

Journal of Advanced Research, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

After significant advancements in tumor treatment, personalized cell therapy based on chimeric antigen receptors (CAR) holds promise for transforming the management of various diseases. CAR-T therapy, first approved CAR product, has demonstrated therapeutic potential treating infectious diseases, autoimmune disorders, and fibrosis. CAR-macrophages (CAR-Ms) are emerging as a promising approach immune particularly solid highlighting feasibility using macrophages to eliminate pathogens abnormal cells.

Язык: Английский

Процитировано

1

Fibroblast-derived CXCL14 aggravates crystalline silica–induced pulmonary fibrosis by mediating polarization and recruitment of interstitial macrophages DOI
Yichuan You, Haoyang Yuan, Min Hui

и другие.

Journal of Hazardous Materials, Год журнала: 2023, Номер 460, С. 132489 - 132489

Опубликована: Сен. 8, 2023

Язык: Английский

Процитировано

16

Integrative transcriptomics and proteomics analysis reveal the protection of Astragaloside IV against myocardial fibrosis by regulating senescence DOI Creative Commons
Lipeng Shi, Jingwei Deng, Jun He

и другие.

European Journal of Pharmacology, Год журнала: 2024, Номер 975, С. 176632 - 176632

Опубликована: Май 6, 2024

Myocardial fibrosis (MF) is a pivotal pathological process implicated in various cardiovascular diseases, particularly heart failure. Astragaloside IV (AS-IV), natural compound derived from Astragalus membranaceus, possesses potent cardioprotective properties. However, the precise molecular mechanisms underlying its anti-MF effects, relation to senescence, remain elusive. Thus, this study aimed investigate therapeutic potential and of AS-IV treating ISO-induced MF mice, employing transcriptomics, proteomics, vitro, vivo experiments. We assessed positive effects on using HE staining, Masson ELISA, immunohistochemical transthoracic echocardiography, transmission electron microscopy, DHE fluorescence staining. Additionally, we elucidated regulatory role through comprehensive transcriptomics proteomics analyses, complemented by Western blotting RT-qPCR validation pertinent pathways. Our findings demonstrated that treatment markedly attenuated myocardial injury oxidative stress, concomitantly inhibiting release SASPs. Furthermore, integrated analyses revealed mechanism was associated with regulating cellular senescence p53 signaling pathway. These results highlight exerts not only stress but also modulating

Язык: Английский

Процитировано

6

BMP6, a potential biomarker of inflammatory fibrosis and promising protective factor for dilated cardiomyopathy DOI Creative Commons
Feng Jiang,

Jiayang Tang,

Xiaoqi Wei

и другие.

Chinese Medicine, Год журнала: 2025, Номер 20(1)

Опубликована: Янв. 15, 2025

Dilated cardiomyopathy (DCM) stands as one of the most prevalent and severe causes heart failure. Inflammation plays a pivotal role throughout progression DCM to failure, while age acts natural predisposing factor for all cardiovascular diseases. These two factors often interact, contributing cardiac fibrosis, which is both common manifestation pathogenic driver adverse remodeling in DCM-induced Bulk RNA-seq, single-cell Mendelian randomization analysis, animal model construction, BMP6 knockdown were utilized identify validate potential specific markers targets intervention We found that hearts exhibit pronounced inflammatory cell infiltration fibrosis. Both bulk RNA-seq analyses revealed aberrant expression specifically fibroblasts. The ROC curve underscores high specificity relation DCM, analysis further confirms protective against DCM. Notably, led decrease SMAD6 marked elevation COL1A1 levels, indicating its antifibrotic role. emerges promising biomarker functional exerting an effect therapeutic target.

Язык: Английский

Процитировано

0

Cellular Senescence and Cardiovascular Aging DOI

Dharmesh Kapoor,

Imteyaz Qamar

Опубликована: Янв. 1, 2025

Процитировано

0

Loss of macrophage fibroblast growth factor 12 attenuates cardiac fibrosis in pressure-overloaded myocardium DOI

Santie Li,

Mei Xue, Junjie Lu

и другие.

International Immunopharmacology, Год журнала: 2025, Номер 154, С. 114614 - 114614

Опубликована: Апрель 7, 2025

Язык: Английский

Процитировано

0